Annexon (NASDAQ: ANNX)
Annexon Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Annexon Company Info
Annexon, Inc. is a clinical-stage biopharmaceutical company, which develops a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, eye and brain. It offers drugs that control or target huntington’s and alzheimer’s disease, multiple sclerosis, glaucoma, parkinson’s disease, and spinal muscular atrophy. The company was founded by Ben Barres and Arnon Rosenthal on March 3, 2011 and is headquartered in Brisbane, CA.
News & Analysis
Why Shares of Annexon Are Plummeting Thursday
Mixed trial results on a geographic atrophy eye drug led investors to sell the biotech stock.
Why Annexon Biosciences Stock Plummeted 34% Today
Investors were unimpressed by the biotech's latest clinical update.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.